Influence of different resistance traits on the competitive growth of Haemophilus influenzae in antibiotic-free medium and selection of resistant populations by different β-lactams: An in vitro pharmacodynamic approach

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 6, 2009, Pages 1215-1222

  González, Natalia ^a   Aguilar, Lorenzo ^a   Alou, Luis ^a   Giménez, Maria Jose ^a   Sevillano, David ^a   Torrico, Martha ^a   Cafini, Fabio ^a   Coronel, Pilar ^b   Prieto, Jose ^a  

^a SCHOOL OF MEDICINE   (Spain)

^b Tedec Meiji Farma SA   (Spain)

Author keywords

Acid; Cefditoren; In vitro simulation

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; BETA LACTAMASE; CEFDITOREN; CEFUROXIME; RIFAMPICIN; TRIMETHOPRIM;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EXPOSURE; DRUG HALF LIFE; GENE MUTATION; HAEMOPHILUS INFLUENZAE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; TIME TO MAXIMUM PLASMA CONCENTRATION;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; BETA-LACTAMS; CEFUROXIME; CEPHALOSPORINS; COCULTURE TECHNIQUES; COLONY COUNT, MICROBIAL; HAEMOPHILUS INFLUENZAE; HUMANS; MICROBIAL SENSITIVITY TESTS; SELECTION (GENETICS);

EID: 65749088481     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp097     Document Type: Article

References (44)

1. Musher DM. Streptococcus pneumoniae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier Churchill Livingstone, 2005; 2392-411.
2. Sá-Leão R, Tomasz A, Santos Sanches I et al. Pilot study of the genetic diversity of the pneumococcal nasopharyngeal flora among children attending day care centers. J Clin Microbiol 2002; 40 3577-85.
3. Murthy TF. Haemophilus influenzae. In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas, and Bennett Principles and Practice of Infectious Diseases, 6th edn. Philadelphia: Elsevier Churchill Livingstone, 2005; 2661-9.
4. Smith-Vaughan HC, Leach AJ, Shelby-James TM et al. Carriage of multiple ribotypes of non-encapsulated Haemophilus influenzae in aboriginal infants with otitis media. Epidemiol Infect 1996; 116: 177-83.
5. Sá-Leão R, Nunes S, Brito-Avô A et al. High rates of transmission of and colonization by Streptococcus pneumoniae and Haemophilus influenzae within a day care center revealed in a longitudinal study. J Clin Microbiol 2008; 46: 225-34.
6. Gómez J, Ruiz-Gómez J, Hernández-Cardona JL et al. Antibiotic resistance patterns of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis: A prospective study in Murcia, Spain, 1983-1992. Chemotherapy 1994; 40: 299-303.
7. Nissinen A, Grönroos P, Huovinen P et al. Development of beta-lactamase-mediated resistance to penicillin in middle-ear isolates of Moraxella catarrhalis in Finnish children, 1978-1993. Clin Infect Dis 1995; 21: 1193-6.
8. Seki H, Kasahara Y, Ohta K et al. Increasing prevalence of ampicillin-resistant, non-beta-lactamase-producing strains of Haemophilus influenzae in children in Japan. Chemotherapy 1999; 45: 15-21.
9. García-Cobos S, Campos J, Lázaro E et al. Ampicillin-resistant non-beta-lactamase-producing Haemophilus influenzae in Spain: Recent emergence of clonal isolates with increased resistance to cefotaxime and cefixime. Antimicrob Agents Chemother 2007; 51: 2564-73.
10. Sevillano D, Giménez MJ, Cercenado E et al. Genotypic versus phenotypic characterization, with respect to β-lactam susceptibility, of Haemophilus influenzae isolates exhibiting decreased susceptibility to β-lactam resistance markers. Antimicrob Agents Chemother 2009; 53: 267-70.
11. Matic V, Bozdogan B, Jacobs MR et al. Contribution of beta-lactamase and PBP amino acid substitutions to amoxicillin/ clavulanate resistance in beta-lactamase-positive, amoxicillin/ clavulanate-resistant Haemophilus influenzae. J Antimicrob Chemother 2003; 52: 1018-21.
12. Pérez-Trallero E, García-de-la-Fuente C, García-Rey C et al Geographical and ecological analysis of resistance, coresistance, and coupled resistance to antimicrobials in respiratory pathogenic bacteria in Spain. Antimicrob Agents Chemother 2005; 49: 1965-72.
13. Sevillano D, Aguilar L, Alou L et al. Effects of antimicrobials on the competitive growth of Streptococcus pneumoniae: A pharmacodynamic in vitro model approach to selection of resistant populations. J Antimicrob Chemother 2006; 58: 794-801.
14. Cafini F, Aguilar L, Sevillano D et al. Decrease in bacterial load versus resistance selection of pneumococcal subpopulations by beta-lactam physiological concentrations over time: An in vitro pharmacodynamic simulation. Microb Drug Resist 2008; 14: 13-21.
15. Torrico M, Aguilar L, González N et al. Influence of TEM-1 beta-lactamase on the pharmacodynamic activity of simulated total versus free-drug serum concentrations of cefditoren (400 milligrams) versus amoxicillin-clavulanic acid (2,000/125 milligrams) against Haemophilus influenzae strains exhibiting an N526K mutation in the ftsI gene. Antimicrob Agents Chemother 2007; 51: 3699-706.
16. Dabernat H, Delmas C, Seguy M et al. Diversity of beta-lactam resistance-conferring amino acid substitutions in penicillin-binding protein 3 of Haemophilus influenzae. Antimicrob Agents Chemother 2002; 46: 2208-18.
17. Scriver SR, Walmsley SL, Kau CL et al. Determination of susceptibilities of Canadian isolates of Haemophilus influenzae and characterization of their β-lactamases. Antimicrob Agents Chemother 1994; 38: 1678-80.
18. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
19. Blaser J, Stone BB, Zinner SH. Two compartment kinetic model with multiple artificial capillary units. J Antimicrob Chemother 1985; 15 Suppl A: 131-7.
20. Mulford D, Mayer M, Witt G. Effect of age and gender on the pharmacokinetics of cefditoren. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 310. American Society for Microbiology, Washington, DC, USA.
21. Mulford D, Mayer M, Witt G. Effect of renal impairment on the pharmacokinetic of cefditoren. In: Abstracts of the Fortieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, 2000. Abstract 311. American Society for Microbiology,Washington, DC, USA.
22. Finn A, Straughn A, Meyer M et al. Effect of dose and food on the bioavailability of cefuroxime axetil. Biopharm Drug Dispos 1987; 8: 519-26.
23. Sommers DK, Van Wyk M, Williams PE et al. Pharmacokinetics and tolerance of cefuroxime axetil in volunteers during repeated dosing. Antimicrob Agents Chemother 1984; 25: 344-7.
24. Augmentin Package Insert. www.fda.gov (9 February 2009, date last accessed).
25. Wellington K, Curran MP. Cefditoren pivoxil: A review of its use in the treatment of bacterial infections. Drugs 2004; 64: 2597-618.
26. Cefuroxime-axetil Package Insert. www.fda.gov (9 February 2009, date last accessed).
27. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM, White LO et al., eds. Clinical Antimicrobial Assays, 1st edn. Oxford: Oxford University Press, 1999; 35-44.
28. Gomez-Lus ML, Gimenez MJ, Prieto J et al. Effect of polymorphonuclear neutrophils on serum bactericidal activity against Streptococcus pneumoniae after amoxicillin administration. Eur J Clin Microbiol Infect Dis 1998; 17: 40-3.
29. White R, Friedrich L, Burgess D et al. Comparative in vitro pharmacodynamics of imipenem and meropenem against Pseudomonas aeruginosa. Antimicrob Agents Chemother 1996; 40: 904-8.
30. Alou L, Aguilar L, Sevillano D et al. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers. J Antimicrob Chemother 2005; 55: 742-7.
31. Firsov AA, Saverino D, Ruble M et al. Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: Enzyme activity versus MIC. Antimicrob Agents Chemother 1996; 40: 734-8.
32. Martin M, Aguilar L, Balcabao IP et al. In-vitro pharmacodynamic simulation of clavulanic acid concentrations: Effect on Staphylococcus aureus and Haemophilus influenzae beta-lactamase activity. J Antimicrob Chemother 1997; 39: 290-2.
33. Prieto J, Aguilar L, Gimenez MJ et al. In vitro activities of co-amoxiclav at concentrations achieved in human serum against the resistant subpopulation of heteroresistant Staphylococcus aureus: a controlled study with vancomycin. Antimicrob Agents Chemother 1998; 42: 1574-7.
34. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Eighteenth Informational Supplement, M100-S18. CLSI, Wayne, PA, USA, 2008.
35. Gillespie SH, Voelker LL, Dickens A. Evolutionary barriers to quinolone resistance in Streptococcus pneumoniae. Microb Drug Resist 2002; 8: 79-84.
36. Rozen DE, McGee L, Levin BR et al. Fitness costs of fluoroquinolone resistance in Streptococcus pneumoniae. Antimicrob Agents Chemother 2007; 51: 412-6.
37. Nuermberger EL, Bishai WR. Antibiotic resistance in Streptococcus pneumoniae: What does the future hold? Clin Infect Dis 2004; 38 Suppl 4: S363-71.
38. Sevillano D, Giménez MJ, Alou L et al. Effects of human albumin and serum on the in vitro bactericidal activity of cefditoren against penicillin-resistant Streptococcus pneumoniae. J Antimicrob Chemother 2007; 60: 156-8.
39. Sevillano D, Aguilar L, Alou L et al. High protein binding and cidal activity against penicillin-resistant S. pneumoniae: A cefditoren in vitro pharmacodynamic simulation. PLoS ONE 2008; 3: E2717.
40. Firsov AA, Smirnova MV, Lubenko IY et al. Testing the mutant selection window hypothesis with Staphylococcus aureus exposed to daptomycin and vancomycin in an in vitro dynamic model. J Antimicrob Chemother 2006; 58: 1185-92.
41. Schmidt S, Röck K, Sahre M et al. Effect of protein binding on the pharmacological activity of highly bound antibiotics. Antimicrob Agents Chemother 2008; 52: 3994-4000.
42. Lamp KC, Rybak MJ. Teicoplanin and daptomycin bactericidal activities in the presence of albumin or serum under controlled conditions of pH and ionized calcium. Antimicrob Agents Chemother 1993; 37: 605-9.
43. Alou L, Aguilar L, Giménez MJ et al. Activity of serum concentrations of daptomycin vs. vancomycin against vancomycin-susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: An in vitro pharmacodynamic simulation. Eur J Clin Microbiol Infect Dis 2008; 27: 1009-11.
44. Cafini F, Aguilar L, González N et al. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives. J Antimicrob Chemother 2007; 59: 1185-9.